Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC cut its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 94.9% during the 1st quarter, Holdings Channel reports. The firm owned 16,402 shares of the company’s stock after selling 305,893 shares during the period. Janus Henderson Group PLC’s holdings in Harmony Biosciences were worth $459,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HRMY. EverSource Wealth Advisors LLC grew its holdings in Harmony Biosciences by 589.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after acquiring an additional 643 shares during the period. Allworth Financial LP lifted its holdings in Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after acquiring an additional 602 shares during the last quarter. Leonteq Securities AG bought a new position in shares of Harmony Biosciences during the 4th quarter valued at about $30,000. National Bank of Canada FI bought a new position in shares of Harmony Biosciences during the 3rd quarter valued at about $40,000. Finally, Clearstead Advisors LLC grew its stake in shares of Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after purchasing an additional 699 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HRMY. Needham & Company LLC increased their target price on shares of Harmony Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday. Truist Financial upped their price target on Harmony Biosciences from $29.00 to $34.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Harmony Biosciences in a research report on Thursday, July 16th. Finally, UBS Group restated a “neutral” rating and issued a $37.00 target price on shares of Harmony Biosciences in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $45.50.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $39.00 on Tuesday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 12.66, a P/E/G ratio of 0.37 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87. The company has a current ratio of 3.48, a quick ratio of 3.45 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $35.34 and a 200 day simple moving average of $32.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, August 4th. The company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The firm had revenue of $261.28 million for the quarter, compared to the consensus estimate of $250.77 million. During the same quarter in the previous year, the company posted $0.92 earnings per share. The business’s quarterly revenue was up 30.3% compared to the same quarter last year. As a group, sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 3.62 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.